| ZYNEXT-VENTURES-USA-LLC |
ZYNEXT-VENTURES-USA-LLC |
85%
|
we accounted for the transaction under ASC 610‑20, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets. We recognized a $ 40.4 million gain on Zydus asset sale in our Condense… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
— 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortization period of our finite-lived intangible assets is 9 years. Amortization expense related to acquired intangibles is estimate… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from AGEN graph: — 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortization period of our finite-lived intangible as… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from AGEN graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from AGEN graph: Reciprocal relationship from BMYM… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
— 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortization period of our finite-lived intangible assets is 9 years. Amortization expense related to acquired intangibles is estimate… |
| GILD |
Gilead Sciences, Inc. |
72%
|
— 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortization period of our finite-lived intangible assets is 9 years. Amortization expense related to acquired intangibles is estimate… |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from AGEN graph: — 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortization period of our finite-lived intangible a… |
| INKT |
MiNK Therapeutics, Inc. |
72%
|
Reciprocal relationship from INKT graph: Reciprocal relationship from AGEN graph: ser Upsize Option liability and equity-classified Ligand Warrants were recognized based on their fair values and the … |
| INKT |
MiNK Therapeutics, Inc. |
72%
|
ser Upsize Option liability and equity-classified Ligand Warrants were recognized based on their fair values and the residual was allocated to a liability related to the sale of future royalties and … |
| LGND |
Ligand Pharmaceuticals Incorporated |
72%
|
— 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortization period of our finite-lived intangible assets is 9 years. Amortization expense related to acquired intangibles is estimate… |
| LGND |
Ligand Pharmaceuticals Incorporated |
72%
|
Reciprocal relationship from LGND graph: Reciprocal relationship from AGEN graph: — 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortization period of our finite-lived intangible a… |
| URGN |
UroGen Pharma Ltd. |
72%
|
— 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortization period of our finite-lived intangible assets is 9 years. Amortization expense related to acquired intangibles is estimate… |
| URGN |
UroGen Pharma Ltd. |
72%
|
Reciprocal relationship from URGN graph: Reciprocal relationship from AGEN graph: — 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortization period of our finite-lived intangible a… |
| ZYDUS-LIFESCIENCES-LIMITED |
ZYDUS-LIFESCIENCES-LIMITED |
62%
|
Sri Lanka (the “Territory”) in exchange for a royalty on net sales at a rate of 5 %, as may be adjusted by the occurrence of certain contingencies, for a period ending at the later of the expiration … |
